Reata Presents Bardoxolone Study Data That Spurred Abbott Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The Phase IIb study shows the drug can reverse the progression of chronic kidney disease, making it a potential first-in-class treatment.
You may also be interested in...
Reata Hopes To Beat Competition To Market With Abbott Deals
Reata Pharmaceuticals hopes the strength of its partnerships and intellectual property will allow it to get an edge on a hot market.
Reata Readies Bardoxolone For Phase III Looking At Kidney Function Outcomes
Further Phase II data show biomarker evidence, and Reata will now look to a 1,600-patient Phase III trial to prove the drug can lead to improved kidney function.
Reata Readies Bardoxolone For Phase III Looking At Kidney Function Outcomes
Further Phase II data show biomarker evidence, and Reata will now look to a 1,600-patient Phase III trial to prove the drug can lead to improved kidney function.